Table 7.
Biomarker correlates of plasma and urine markers in patients treated with bortezomib, carboplatin and etoposide
| Specimen time point | Number of specimens | Mean±SD | Standard error (min-max) |
|---|---|---|---|
| VEGF (pg/ml) | |||
| Cycle 1 day 1 | 7 | 85.3957±98.97 | 37.41 (9.30–236.0) |
| Cycle 1 day 15 | 3 | 30.1933±20.10 | 11.60 (14.94–52.98) |
| Cycle 2 day 1 | 8 | 142.7712±147.30 | 52.08 (12.30–420.10) |
| Cycle 2 day 15 | 5 | 12.10±10.78 | 4.82 (3.04–29.37) |
| Plasma bFGF (pg/ml) | |||
| Cycle 1 day 1 | 15 | 28.1047±30.93 | 7.99 (0.92–97.83) |
| Cycle 1 day 15 | 12 | 20.5392±15.09 | 4.36 (1.79–51.59) |
| Cycle 2 day 1 | 11 | 37.5909±26.34 | 7.94 (1.52–83.13) |
| Cycle 2 day 15 | 6 | 37.0867±41.26 | 16.84 (7.54–119.04) |
| Plasma e-selectin (ng/ml) | |||
| Cycle 1 day 1 | 15 | 50.9520±26.72 | 6.90 (24.86–116.36) |
| Cycle 1 day 15 | 12 | 40.2058±24.22 | 6.99 (15.00–95.97) |
| Cycle 2 day 1 | 11 | 45.6273±25.22 | 7.60 (21.55–99.23) |
| Cycle 2 day 15 | 6 | 37.5533±26.75 | 10.92 (14.16–88.01) |
| Plasma p-selectin (ng/ml) | |||
| Cycle 1 day 1 | 14 | 54.4321±52.34 | 13.99 (13.35–185.06) |
| Cycle 1 day 15 | 6 | 28.8767±16.45 | 6.71 (14.12–55.87) |
| Cycle 2 day 1 | 9 | 94.9711±72.36 | 24.12 (16.77–256.22) |
| Cycle 2 day 15 | 3 | 35.0967±7.44 | 4.29 (29.04–13.40) |
| Urine bFGF (pg/ml) | |||
| Cycle 1 day 1 | 8 | 2.9675±3.76 | 1.32 (0.11–11.53) |
| Cycle 1 day 15 | 9 | 2.9589±3.19 | 1.06 (0.32–10.37) |
| Cycle 2 day 1 | 8 | 4.7200±9.32 | 3.29 (0.20–27.39) |
| Cycle 2 day 15 | 6 | 7.1800±7.20 | 2.94 (1.12–19.79) |